Managing BTK Inhibitor Toxicities

CE / CME

Optimizing the Use of BTK Inhibitors in B-Cell Malignancies: Addressing BTK Inhibitor Toxicities

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour

Released: September 29, 2021

Expiration: September 28, 2022

Christopher R. Flowers
Christopher R. Flowers, MD, MS

Activity

Progress
1
Course Completed
References

  • Pileri SA, Falini B. Mantle cell lymphoma. Haematologica. 2009;94:1488-1492.
  • Bahler DW, Pindzola JA, Swerdlow SH. Splenic marginal zone lymphomas appear to originate from different B cell types. Am J Pathol. 2002;161:81-88.
  • Darwiche W, Gubler B, Marolleau J, et al. Chronic lymphocytic leukemia B-Cell normal cellular counterpart: clues from a functional perspective. Front Immunol. 2018;9:683.
  • MedlinePlus.gov. Waldenström macroglobulinemia. medlineplus.gov/genetics/condition/waldenstrom-macroglobulinemia. Accessed September 17, 2021.
  • Kraus M, Alimzhanov MB, Rajewsky N, et al. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell. 2004;117:787-800.
  • Buchner M and Müschen M. Targeting the B-cell receptor signaling pathway in B lymphoid malignancies. Curr Opin Hematol. 2014;21:341-349.
  • Liu W, Tolar P, Song W, et al. Editorial: BCR signaling and B cell activation. Front Immunol. 2020;11:45.
  • Seda V, Mraz M. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol. 2015;94:193-205.
  • Ibrutinib [prescribing information]. Horsham, PA: Janssen; 2020.
  • Acalabrutinib [prescribing information]. Wilmington, DE: AstraZeneca; 2019.
  • Zanubrutinib [prescribing information]. San Mateo, CA: BeiGene; 2019.
  • Kaptein A, De Bruin G, Emmelot-van Hoek M, et al. Potency and selectivity of BTK Inhibitors in clinical development for B-Cell malignancies. Presented at: 60th American Society of Hematology Meeting and Exposition; December 1-4, 2018. Abstract 1871.
  • Berglof A, Hamsay A, Meinke S, et al. Targets for ibrutinib beyond B Cell malignancies. Scand J Immunol. 2015;82:208-217.
  • Estupiñán HY, Berglöf A, Rula Zain, et al. Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol. 2021;9:630942.
  • Xu W, Yang S, Zhou K, et al. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. J Hematol Oncol. 2020;13:48.
  • Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019;133:1298-1307.
  • Herman SEM, Niemann CU, Farooqui M, et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia. 2014;28:2188-2196.
  • Spaargaren M, de Rooij MFM, Kater AP, et al. BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future. Oncogene. 2015;34:2426-2436.
  • Owen C, Berinstein NL, Christofides A, et al. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. Curr Oncol. 2019;26:e233-e240.
  • Aguilar C. Ibrutinib-related bleeding: pathogenesis, clinical implications and management. Blood Coagul Fibrinolysis. 2018;29:481-487.
  • National Comprehensive Cancer Network. Clinical practice guidelines in oncology: chronic lymphocytic leukemia/small lymphocytic lymphoma. v4.2021. nccn.org. Accessed September 17, 2021.
  • McNally GA, Long JM, Brophy LR, et al. Ibrutinib: implications for use in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. J Adv Pract Oncol. 2015;6:420-431.
  • Shatzel JJ, Olson SR, Tao DL, et al. Ibrutinib-associated bleeding; pathogenesis, management, and risk reduction strategies. J Thromb Haemost. 2017;15:835-847.
  • Moore DC and Thompson D. A review of the bruton tyrosine kinase inhibitors in B-cell malignancies. J Adv Pract Oncol. 2021;12:439.
  • Taplitz RA, Kennedy EB, Bowe EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American society of clinical oncology and infectious diseases society of America clinical practice guideline update. J Clin Oncol. 2018;36:1443-1453.
  • Mato AR, Roeker LE, Lamanna N, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136:1134-1143.
  • Williamson EJ, Walker AJ, Bhaskaran A, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430-436.
  • Wen T, Wang J, Shi Y, et al. Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances. Leukemia. 2021;35:312-332.
  • Bond DA, Huang Y, Fisher JL, et al. Second cancer incidence in CLL patients receiving BTK inhibitors. Leukemia. 2020;34:3197-3205.
  • Stuhlinger MC, Weltermann A, Staber P, et al. Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk. Wien Klin Wochenschr. 2019;132:97-109.
  • Framinghan Heart Study. Framingham Heart Study AF score (10-year risk). framinghamheartstudy.org/fhs-risk-functions/atrial-fibrillation-10-year-risk/. Accessed September 17, 2021.
  • Lipsky A, Lamanna N. Managing toxicities of bruton tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program. 2020;2020:336-345.
  • Segal EM, Flood MR, Mancini RS, et al. Oral chemotherapy and food and drug interactions: a comprehensive review of the literature. J Oncol Pract. 2014;10:e255-e268.
  • Veerman GD, Hussaarts KG, Jansman FG, et al. Clinical implications of food-drug interactions with small-molecule kinase inhibitors. Lancet Oncol. 2020;21:e265-e279.
  • ClinicalTrials.gov. A phase 3 study of ibrutinib (PCI-32765) versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia (RESONATE). clinicaltrials.gov/ct2/show/NCT01578707. Accessed September 17, 2021.
  • Munir T, Brown JR, O’Brien S. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94:1353-1363.
  • Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103:874-879.
  • Wicze TE, Levine LB, Brumbaugh J, et al. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv. 2017;1:1739-1748.
  • Brown JR, Moslehi J, O’Brien S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102:1796-1805.
  • Dickerson T, Wiczer T, Waller A, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019;134:1919-1928.
  • Brown JR. Moslehi J. Ewer MS, et al. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: an integrated analysis. Br J Haematol. 2019;184:558-569.
  • National Comprehensive Cancer Network. Clinical practice guidelines in oncology: B-cell lymphomas. v.4.2021. nccn.org. Accessed September 17, 2021.
  • ClinicalTrials.gov. Ibrutinib and rituximab compared with fludarabine phosphate, cyclophosphamide, and rituximab in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. clinicaltrials.gov/ct2/show/NCT02048813. Accessed September 17, 2021.
  • Shanafelt TD, Wang XV, Kay, NE, et al. Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381:432-443.
  • ClinicalTrials.gov. Rituximab and bendamustine hydrochloride, rituximab and ibrutinib, or ibrutinib alone in treating older patients with previously untreated chronic lymphocytic leukemia. clinicaltrials.gov/ct2/show/NCT01886872. Accessed September 17, 2021.
  • Woyach JA, Ruppert AS, Heerema, NA, et al. Ibrutinib alone or in combination with rituximab produces superior progression free survival (PFS) compared with bendamustine plus rituximab in untreated older patients with chronic lymphocytic leukemia (CLL): results of Alliance North American Intergroup Study A041202. Presented at: 60th American Society of Hematology Meeting and Exposition; December 1-4, 2018. Abstract 6.
  • Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379:2517-2528.
  • ClinicalTrials.gov. ACP-196 (acalabrutinib), a novel bruton tyrosine kinase (BTL) Inhibitor, for treatment of chronic lymphocytic leukemia. clinicaltrials.gov/ct2/show/NCT02029443. Accessed September 17, 2021.
  • Byrd JC, Woyach JA, Furman RR, et al. Acalabrutinib in treatment-naive (TN) chronic lymphocytic leukemia (CLL): updated results from the phase 1/2 ACE-CL-001 study. Presented at: 60th American Society of Hematology Meeting and Exposition; December 1-4, 2018. Abstract 692.
  • Byrd JC, Woyach JA, Furman RR, et al. Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood. 2021;137:3327-3338.
  • Awan FT, Schuh A, Brown JR, et al. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv. 2019;3:1553-1562.
  • Rogers KA, Thompson PA, Allan JN, et al. Phase 2 study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica. 2021[Epub ahead of print].
  • ClinicalTrials.gov. Study of acalabrutinib (ACP-196) versus ibrutinib in previously treated subjects with high risk CLL. clinicaltrials.gov/ct2/show/NCT02477696. Accessed September 17, 2021.
  • Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021[Epub ahead of print].
  • ClinicalTrials.gov. A study of zanubrutinib (BGB-3111) versus ibrutinib in participants with relapsed/refractory chronic lymphocytic leukemia (ALPINE). clinicaltrials.gov/ct2/show/NCT03734016. Accessed September 17, 2021.
  • Hillmen P, Eichorst B, Brown JR, et al. First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractor chronic lymphocytic leukemia/small lymphocytic lymphoma. Presented at: 2021 European Hematology Association Virtual Congress; June 9-17, 2021. Abstract LBA1900.
  • Tam CS, Opat S, D’Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020;136:2038-2050.
  • US Food and Drug Administration. FDA approves zanubrutinib for Waldenström’s macroglobulinemia. fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanubrutinib-waldenstroms-macroglobulinemia. Accessed September 17, 2021.
  • ClinicalTrials.gov. Study of evaluate efficacy and safety of BGB-3111 in participants with relapsed or refractory mantle cell lymphoma (MCL). clinicaltrials.gov/ct2/show/NCT03206970. Accessed September 17, 2021.
  • Song Y, Zhou, K, Zou D, et al. Safety and activity of the investigational bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) in patients with mantle cell lymphoma from a phase 2 trial. Presented at: 60th American Society of Hematology Meeting and Exposition; December 1-4, 2018. Abstract 148.
  • Song Y, Zhou K, Zou D, et al. Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of bruton's tyrosine kinase. Clin Cancer Res. 2020;26:4216-4224.